Megestrol Shortage: What Providers and Prescribers Need to Know in 2026

The Megestrol acetate tablet shortage that emerged in mid-2025 has created real clinical challenges for oncologists, infectious disease specialists, palliative care providers, and primary care physicians. When three of the major generic tablet manufacturers — Strides Pharma, Major Pharmaceuticals, and Teva — placed 20 mg and 40 mg tablets on simultaneous back order, the ripple effect reached patients across the country. This article provides an evidence-based, clinically focused overview for prescribers navigating this supply disruption.

Shortage Summary: Which Products Are Affected?

The ASHP drug shortage database (first posted May 23, 2025) listed the following as affected:

Megestrol acetate 20 mg tablets (100-count) — multiple manufacturers on back order

Megestrol acetate 40 mg tablets (100-count, 500-count, unit-dose packs) — multiple manufacturers on back order

Oral suspensions (40 mg/mL and Megace ES 125 mg/mL) — intermittent supply challenges reported but covered under separate shortage notices

Note: Manufacturers' estimated resupply dates (mid-to-late 2025) are not guarantees. Pharmacy-level availability typically lags manufacturer shipment dates by several weeks as inventory replenishes through the distribution chain.

Clinical Risks of Abrupt Megestrol Discontinuation

Long-term megestrol acetate use suppresses the hypothalamic-pituitary-adrenal (HPA) axis. ACTH stimulation testing has demonstrated frequent asymptomatic adrenal suppression in chronic users. Abrupt discontinuation — particularly in stressed states such as infection, surgery, or intercurrent illness — can precipitate clinically significant adrenal insufficiency. Symptoms include hypotension, nausea, vomiting, dizziness, and weakness. Providers should counsel patients to report these symptoms and should consider stress-dose glucocorticoid coverage for patients who have been on high-dose Megestrol (400-800 mg/day) for more than 4-6 weeks.

For patients currently on Megestrol who may have supply interruptions, a planned taper is preferable to abrupt cessation. Consult endocrinology if you have concerns about HPA axis suppression.

Alternatives by Clinical Indication

The appropriate alternative depends on the original indication. Below are evidence-informed options organized by use case.

AIDS-Related Anorexia/Cachexia

Dronabinol (Marinol) 2.5 mg BID: FDA-approved for AIDS-related anorexia. Schedule III. Efficacy in promoting weight gain is more modest than Megestrol. Watch for psychoactive effects, particularly in elderly patients or those with psychiatric comorbidities. Note: dronabinol itself has faced intermittent supply challenges.

Mirtazapine 7.5-15 mg QHS: Off-label; widely available; useful in patients with co-occurring depression, insomnia, or nausea. Generally well-tolerated. Lower doses (7.5 mg) often produce more appetite stimulation than higher doses.

Oxandrolone 10-20 mg/day: Schedule III anabolic steroid; FDA-approved for weight gain in wasting states. Promotes lean muscle mass (clinically distinct from Megestrol's predominantly fat-mass gain). Monitor LFTs and hormonal effects.

Advanced Breast Cancer (Palliative)

Aromatase inhibitors (letrozole, anastrozole, exemestane): Generally preferred over Megestrol for hormone receptor-positive breast cancer given superior efficacy and tolerability data. Megestrol is considered second- or third-line for most current guidelines.

Medroxyprogesterone acetate: Structurally related progestin with similar hormonal mechanisms. Can be considered when Megestrol is unavailable, though dosing and evidence base differ. Carries similar thromboembolic risk profile.

Endometrial Cancer (Palliative)

Medroxyprogesterone acetate (high dose, 200-1000 mg/day): The most established Megestrol alternative for endometrial carcinoma. Efficacy data are available from comparative trials. Adjust dose under oncology supervision.

Cancer Cachexia / Palliative Appetite Stimulation

Dexamethasone 1-4 mg/day or prednisone 5-10 mg/day: Short-term appetite improvement; limited to 4-6 weeks due to well-known glucocorticoid adverse effect profile. Appropriate in end-of-life settings or as a bridge.

Mirtazapine 7.5-15 mg QHS: Useful when appetite stimulation is needed in combination with nausea management or mood support. Evidence base is primarily observational.

Documentation Considerations for Prior Authorization

If switching to an alternative that requires prior authorization, document: the patient's current Megestrol indication and duration of therapy, confirmation of supply unavailability (pharmacy name, date, manufacturer back-order notice if available), the clinical rationale for the selected alternative, and any trials of other agents. This documentation will support appeal if a PA is initially denied.

Helping Your Patients Find Megestrol in Stock

For patients who are not yet ready to switch or who may only need a short-term supply bridge, medfinder for Providers is a tool that contacts pharmacies near your patient to check real-time stock. Your patients provide their medication, dosage, and location, and medfinder calls pharmacies on their behalf — results are texted directly to the patient.

See our full provider workflow guide: How to Help Your Patients Find Megestrol in Stock: A Provider's Guide.